Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus CAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus CAPEX.
ALA-SCALP vs CAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Topical application of a 5% solution to the scalp twice daily.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid